A Phase 1 Study of Neratinib (HKI-272) In Combination With Vinorelbine in Japanese Subjects With Advanced or Metastatic Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 05 Jul 2018
At a glance
- Drugs Neratinib (Primary) ; Vinorelbine (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Puma Biotechnology; Wyeth
- 11 May 2012 Company (Puma Biotechnology) added as reported by ClinicalTrials.gov.
- 15 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Oct 2010 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov.